(Reuters) – A committee of the European Medicines Agency will discuss potential links between a class of diabetes and weight loss drugs such as Novo Nordisk’s Ozempic and suicidal thoughts this week, an agenda from the panel showed on Monday.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
